KLOTHO NEUROSCIENCES RAISES OVER $11 MILLION, RETIRES ALL DEBT, AND EXCEEDS NASDAQ STOCKHOLDERS' EQUITY REQUIREMENT

Rhea-AI Summary

Klotho Neurosciences (NASDAQ: KLTO) has successfully raised over $11 million through the exercise of existing warrants by investors over a ten-day period, with Chardan Capital Markets serving as the exclusive financial advisor. The biogenetics company has strategically utilized $3.1 million of the raised funds to fully extinguish all outstanding debt, achieving a debt-free balance sheet. This financial restructuring has positioned KLTO to exceed the stockholders' equity thresholds required for maintaining NASDAQ listing compliance, addressing a critical regulatory requirement.

Positive

• Raised over $11 million through warrant exercises without need for dilutive new share issuance
• Completely eliminated all debt ($3.1 million) resulting in a debt-free balance sheet
• Expected to meet NASDAQ listing requirements, reducing delisting risk
• Strengthened financial position without taking on new debt obligations

Negative

• Previous non-compliance with NASDAQ listing requirements indicates past financial challenges

Highlights:

• Over $11 Million Raised: Proceeds were generated through the exercise of existing warrants. Chardan Capital Markets was the exclusive financial advisor in connection with public warrant exercises.
• Update on NASDAQ Compliance: Klotho believes it now exceeds the stockholders' equity thresholds required to remain in compliance with NASDAQ listing requirements.
• Zero Debt: Klotho has fully extinguished all outstanding debt, resulting in a debt-free balance sheet.

NEW YORK, June 16, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biogenetics company, today announced that over the course of the last ten days, it raised over $11 million in funding through the exercise of existing warrants by investors. The Company believes that it now surpasses Nasdaq's stockholders' equity requirement requirements outlined in its Nasdaq compliance plan.

In addition, the Company utilized  $3.1 million of the funds raised to extinguish all outstanding debt, resulting in a debt-free balance sheet.

About Klotho Neurosciences, Inc. 
Klotho Neurosciences, Inc. (NASDAQ: KLTO) is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using an important human protein derived from the Company's patented form of the "anti-aging" human Klotho gene (s-KL) and its novel promoter and delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease. The company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. The company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.

For more information, contact:
Investor Contact and Corporate Communications - Jeffrey LeBlanc, CFO
jeff@klothoneuro.com

Website: www.klothoneuro.com

Forward-Looking Statements:

This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company's future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company's inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC") from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC's website, www.sec.gov. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/klotho-neurosciences-raises-over-11-million-retires-all-debt-and-exceeds-nasdaq-stockholders-equity-requirement-302482040.html

SOURCE Klotho Neurosciences, Inc.

FAQ

How much money did Klotho Neurosciences (KLTO) raise in June 2025?

Klotho Neurosciences raised over $11 million through the exercise of existing warrants by investors over a ten-day period in June 2025.

How much debt did KLTO pay off with the raised funds?

KLTO used $3.1 million of the raised funds to extinguish all outstanding debt, resulting in a debt-free balance sheet.

Who was the financial advisor for KLTO's warrant exercises?

Chardan Capital Markets served as the exclusive financial advisor in connection with the public warrant exercises.

How does the $11 million fundraising affect KLTO's NASDAQ listing status?

The fundraising is expected to help KLTO exceed the stockholders' equity thresholds required to remain in compliance with NASDAQ listing requirements.

What is Klotho Neurosciences' current debt status after the June 2025 announcement?

Following the announcement, Klotho Neurosciences has a debt-free balance sheet after fully extinguishing all outstanding debt.